Salick Cardiovascular Group
Salick Cardiovascular Group is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Salick Cardiovascular Group.
Salick Cardiovascular Group is a company.
Key people at Salick Cardiovascular Group.
Key people at Salick Cardiovascular Group.
Salick Cardiovascular Group, also referred to as Salick Cardiovascular Centers, Inc., was a proposed network of comprehensive outpatient cardiovascular centers founded by Dr. Bernard Salick, a pioneering nephrologist and medical entrepreneur.[1][5][8] It aimed to deliver state-of-the-art diagnosis and treatment for cardiovascular diseases—including cerebrovascular, coronary artery, peripheral vascular disease, and related end-stage renal conditions—through 24/7 multidisciplinary facilities offering procedures like surgery, angioplasty, angiography, electrophysiologic testing, and advanced radiology.[1] Backed by $75 million in Series A funding from Private Equity Partners, it targeted cost-efficient, user-friendly care for patients, physicians, and payers, building on Salick's disease-state management model from prior ventures like Salick Health Care.[1][5]
The centers served patients with chronic cardiovascular conditions, solving problems of fragmented care, high hospitalization costs, and limited outpatient access by integrating services with inpatient affiliations and diabetes centers.[1] While specific growth metrics are unavailable, the initiative represented early-stage momentum in the late 1990s healthcare shift toward outpatient "factories" for specialized care, as outlined in its Harvard Business School case study business plan.[8]
Dr. Bernard Salick, born in 1939 and a Queens College/CUNY alumnus (M.D. '60), founded Salick Cardiovascular Centers following his successes in dialysis and cancer care.[1][2] In the 1970s, he built a dialysis chain sold to Damon Corp in 1975 and repurchased in 1983 to launch Salick Health Care, Inc., motivated by his daughter's 1985 sarcoma diagnosis, which inspired 24/7 outpatient cancer centers starting at Cedars-Sinai.[2][3] Salick Health Care expanded to 11 cancer centers, 8 breast centers, and dialysis facilities, went public in 1985 (raising $18M+), and sold to Zeneca (AstraZeneca) in 1997 for $450M after a 50% stake sale in 1995.[2][3][4]
Post-sale, Salick launched new ventures like Bentley Health Care in 1997 for cancer, renal, AIDS, and transplants.[2][4] Drawing on this expertise, he pioneered Comprehensive Cardiovascular Centers via Salick Cardiovascular Centers, Inc., in affiliation with Private Equity Partners, proposing a national rollout with leading practitioners.[1][5][8] This evolved his disease-specific paradigm—first in dialysis and cancer—to cardiovascular care, emphasizing outpatient efficiency amid 1990s managed care trends.[1][6][7]
Salick Cardiovascular Group rode the 1990s managed care and outpatient revolution in U.S. healthcare, shifting from costly inpatient models to integrated, capitated outpatient networks amid rising HMO dominance and cost pressures.[4][6][7] Timing aligned with post-1980s deregulation enabling for-profit specialty chains, as seen in Salick Health Care's growth and Zeneca acquisition, influencing disease management for chronic illnesses.[2][3] Market forces like escalating cardiovascular disease prevalence (leading cause of death) and demands for efficiency favored its model, prefiguring modern ASCs (ambulatory surgery centers) and value-based care.[1]
It influenced the ecosystem by validating specialized outpatient hubs, paving the way for cardiology-focused providers like Citrus Cardiology (unrelated but illustrative of enduring trends).[9] Salick's fixed-price products and guidelines set precedents for oncology/cardiology capitation, adopted by HMOs like Physicians Corporation of America and CIGNA.[4][7]
Salick Cardiovascular Centers exemplified Bernard Salick's visionary push into cardiovascular "factories," but search results indicate it remained a business plan stage without confirmed operational scale, likely absorbed or pivoted amid post-1997 consolidations like AstraZeneca's shifts.[5][8] Next steps historically stalled, with no evidence of national rollout by 2025, reflecting challenges in executing outpatient cardiology amid regulatory hurdles and funding climates.
Future trends like AI-driven diagnostics, telecardiology, and value-based reimbursement could revive similar models, amplifying Salick's legacy in cost-effective chronic care. Its influence endures in modern networks prioritizing outpatient efficiency, tying back to the high-level promise of transforming fragmented cardiovascular treatment into accessible, 24/7 paradigms.[1]
